Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
OS Therapies logo — Targeting Osteosarcoma, Breast Cancer and other Solid Tumors...

OS Therapies

Targeting Osteosarcoma, Breast Cancer and other Solid Tumors to prevent HER2-metastasis and destroy solid tumors.

Founded 2018 United States New York, United States 8 employees Debt Financing Total: $7.00M Health Care, Health and Wellness +1

General Information

Company Name OS Therapies
Founded Year 2018
Location United States New York, United States
Founders / Decision Makers
Team member
Employees 8
Industries Health Care, Health and Wellness, Pharmaceutical
Funding Stage Debt Financing
Social

BounceWatch is an independent company data service, not affiliated with OS Therapies. To contact OS Therapies, visit ostherapies.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does OS Therapies compare?

A PDF of OS Therapies and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting OS Therapies soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About OS Therapies

OS Therapies is a clinical stage research company founded in 2017, with a focus on therapeutic treatments for Osteosarcoma and other solid tumors. The company's slogan, "Targeting Osteosarcoma and other Solid Tumors to prevent metastasis and destroy solid tumors," encapsulates its mission. OS Therapies employs two platform technologies, OST-HER2 to prevent metastasis and OST-tADC to debulk solid tumors. The company operates within the Health Care and Pharmaceutical industries, with its headquarters located in the United States. In its latest funding round, OS Therapies secured a $1.00M investment through Debt Financing on 16 July 2021. The investors in the last round were not disclosed. OS Therapies' focus on addressing critical unmet needs in oncology, combined with its proprietary technologies, positions the company as a compelling player in the fight against solid tumors.

Business keywords: Clinical Stage Therapeutics, Osteosarcoma Treatment, Solid Tumor Therapies, Pediatric Cancer, Oncology, Breast Cancer Treatment, Lung Cancer Treatment, Esophageal Cancer Treatment, Ovarian Cancer Treatment

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Debt Financing $1.00M -
16 Jul 2021
Series A $6.00M 3
K20 Fund Tichenor Ventures NOBLE Capital Markets
K20 Fund, Tichenor Ventures +1
20 Apr 2021

OS Therapies Alternatives & Competitors

View All Alternatives
OS Therapies vs
Vuja De Sciences
Vuja De Sciences

Vuja De is dedicated to developing cancer metastasis treatments that prevent cancer progression and...

Venture round
7 employees
Biotechnology, Health Care
OS Therapies vs
Lisata Therapeutics, Inc.
Lisata Therapeutics, Inc. United States

Targeted Therapy Delivered

Acquired
39 employees
Biotechnology, Health and Wellness
OS Therapies vs
BiPar Sciences
BiPar Sciences

Innovative therapies harnessing the power of PARP inhibitors to combat advanced cancers

Series C
Biotechnology, Health Care
View all alternatives

FAQ About OS Therapies

Targeting Osteosarcoma, Breast Cancer and other Solid Tumors to prevent HER2-metastasis and destroy solid tumors.
OS Therapies was founded in 2018.
OS Therapies is headquartered in New York, United States.
OS Therapies operates in Health Care, Health and Wellness and Pharmaceutical. Its work centres on Clinical Stage Therapeutics, Osteosarcoma Treatment, Solid Tumor Therapies and Pediatric Cancer.
OS Therapies has approximately 8 employees.
OS Therapies has completed 2 funding rounds, raising a total of $7.00M. The latest funding stage is Debt Financing.
Top alternatives and competitors to OS Therapies include Vuja De Sciences, Lisata Therapeutics, Inc., BiPar Sciences, Sensei Bio, OncXerna Therapeutics . These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
OS Therapies and Vuja De Sciences are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for OS Therapies, https://bouncewatch.com/company/os-therapies, updated 30 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout